Low-Grade Glioma – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Low-Grade Glioma – Drugs In Development, 2024 report and make more profitable business decisions.
Low-grade gliomas are benign grade 1 and grade 2 tumors of the brain or spinal cord, according to WHO classification. The development of these tumors may be brought on by environmental variables or genetic abnormalities. The tumor’s size and location affect how it presents itself. Main causes include genetic mutations or environmental factors. Usually seizure is the first sign of a low-grade glioma.
The Low-Grade Glioma drugs in development market research report provide comprehensive information on the therapeutics under development for Low-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Low-Grade Glioma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- Therapeutics in Development: Covering 28 molecules, with 26 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Low-Grade Glioma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Low-Grade Glioma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Low-Grade Glioma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AnHeart Therapeutics IncAnnias Immunotherapeutics Inc
AstraZeneca Plc
BeiGene Ltd
BioMed Valley Discoveries Inc
Boehringer Ingelheim International GmbH
Day One Biopharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Fochon Pharmaceutical Ltd
Fore Biotherapeutics Inc
Hutchison MediPharma Ltd
Immatics NV
Johnson & Johnson
Les Laboratoires Servier SAS
Nascent Biotech Inc
Nerviano Medical Sciences SRL
Novartis AG
Oncovir Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
SpringWorks Therapeutics Inc
Stemline Therapeutics Inc
The Feinstein Institute for Medical Research
University of Pittsburgh